2024 Nasdaq rxrx - Sep 5, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...

 
Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah. Headquarters Location. 41 South Rio Grande Street . Salt Lake City, Utah, 84101,. Nasdaq rxrx

Yet, risky stocks can also often offer attractive upside potential. Let's look at two examples: Recursion Pharmaceuticals ( RXRX 4.40%) and Madrigal Pharmaceuticals ( MDGL 1.83%). These two ...Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ...Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded. RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:... Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...SALT LAKE CITY, July 12, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry ...Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months.Recursion Pharmaceuticals Inc (NASDAQ:RXRX). 7.38. Delayed Data. As of Dec 01. +0.53 / +7.74%. Today's Change. 4.54. Today|||52-Week Range. 16.75. -4.28%. Year- ...On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at …Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Jul 12, 2023 · Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year. Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Recursion Pharmaceuticals (NASDAQ:RXRX) recently gapped higher after receiving a $50 million investment from AI powerhouse Nvidia (NASDAQ:NVDA).With that, Recursion will use NVDA technology to ...Industry. Biotechnology. No executives to display. Corporate headquarters. --, --. Find real-time RXRX - Recursion Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN ... Recursion Pharmaceuticals Stock forecast & analyst price target predictions based on 5 analysts offering 12-months price targets for RXRX in the last 3 months.Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot ... 12 Nis 2023 ... investments in companies including Recursion (NASDAQ: RXRX), which uses automation and deep learning to develop novel therapeutics; Enveda ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. Cathie Wood-led Ark Investment Management on Tuesday snapped up another 236,348 shares of cryptocurrency exchange Coinbase Global Inc (NASDAQ: COIN).. Coinbase has been in a free-fall mode since ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...NASDAQ: RXRX · IEX Real-Time Price · USD. Add to Watchlist 6.96 +0.43 (6.58%) Nov 28, 2023, 3:34 PM EST - Market open. Overview; ... Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an increase of 120.26%. The lowest target is $8.00 and …Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) last month posted second-quarter results. GAAP EPS in the quarter came in at -$0.38. Revenue in the period jumped 42.9% year over year to $11 million.This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $9.00. The …9 Kas 2023 ... ... (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.12 Tem 2023 ... SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company ...Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.Rhumbline Advisers grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 22.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).The fund owned 257,975 shares of the company’s stock after purchasing an additional …Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia.But, since that month’s peak, RXRX’s stock ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...On October 11, 2023, Michael Secora, the Chief Financial Officer (CFO) of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 50,000 shares of the company.In a notable insider transaction, Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023.When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Find the latest Earnings Report Date for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Published: Nov 02, 2023. SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16, 2023.Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest …SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ...RXRX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global …Nov 29, 2023 · 4 brokerages have issued twelve-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $15.00. On average, they anticipate the company's stock price to reach $11.20 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price. The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...Or, we can look back at Recursion Pharmaceuticals. (NASDAQ:RXRX), which I spoke about on Aug. 8.At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create ...Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was incorporated in 2013 and is headquartered in Salt Lake City, Utah. It operates as a clinical-stage biotechnology company, utilizing biology, ...SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...31 Eki 2023 ... Discovering new drugs is no easy task, and one young company that aims to help in that process is Recursion Pharmaceuticals (NASDAQ: RXRX).Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ...The last time I mentioned Recursion Pharmaceuticals (NASDAQ:RXRX), it traded around $10.75 on Aug. 8.While the stock dipped to about $8.58 following that note, there’s still a lot to like here ...Recursion Pharmaceuticals (NASDAQ: RXRX) is investing big in the AI-biotech trend.They recently partnered with NVIDIA (NASDAQ: NVDA) and will receive $50 million dollars with their access to ...The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?Jul 12, 2023 · Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year. On July 21, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported that the European Commission has authorized an orphan drug designation to its inhibitor REC-4881 for the treatment of familial ...Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Nov 27, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This will be used […] Microsoft Corporation Common Stock. $376.39 +0.22 +0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...Today, we take our first look at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead?At the time, Nvidia (NASDAQ: NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …Dec 1, 2023 · In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...16 Nis 2021 ... Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) rings the Nasdaq Stock Market Opening Bell remotely from Salt Lake City, Utah.Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Dec 4, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.12 Tem 2023 ... SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company ...Netflix Inc (NASDAQ:NFLX): Bought 2,490 shares of the movie streaming company, representing about 0.199% of the ETF. Netflix stock closed 1.45% higher at $554.44 on Monday. It has a 52-week high ...Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.On July 21, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported that the European Commission has authorized an orphan drug designation to its inhibitor REC-4881 for the treatment of familial ...15 Kas 2023 ... Graphic designer/iStock via Getty Images. AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday ...Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have ...About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Chris Gibson. Co-Founder/CEO Recursion: a biotech scaling more like a tech company - Nasdaq:RXRX | Reimagining the Future of Biotech. 6y. As we continue building Recursion Pharmaceuticals, we ...Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Nasdaq rxrx

SALT LAKE CITY, May 12, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations .... Nasdaq rxrx

nasdaq rxrx

Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After Hours Volume:... According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.30 Haz 2021 ... ... (Nasdaq: ABCL), Recursion Pharmaceuticals (Nasdaq: RXRX), Zymergen (Nasdaq: ZY), Desktop Metal (NYSE: DM) and Lucira Health (Nasdaq: LHDX).Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals (RXRX 7.88%), and GE Healthcare Technologies (GEHC 1.39%) are already using AI to boost ...Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot ... Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares.Nov 24, 2023 · The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00. Learn more on RXRX's analyst rating history. Do Wall Street analysts like Recursion Pharmaceuticals more than its competitors? Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Pre-Market Stock Quotes ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …SALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it recently received a Prime Rating for ESG performance from the industry-renowned Institutional Shareholder Services (ISS), which is the first time …Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development ...Nov 8, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ... SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...It has been a tumultuous year for the clinical-stage biotech Recursion Pharmaceuticals ( RXRX -2.84%). Earlier this year, the company's shares skyrocketed after it announced a partnership with the ...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed... According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the top stock picks of Samsara BioCapital along with IVERIC bio, Inc. (NASDAQ:ISEE), Sutro Biopharma, Inc. (NASDAQ:STRO) and Forma ...Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES.After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.45%) on July 12, Recursion Pharmaceuticals ( RXRX 10.49%) saw its stock blast off, rising 87% over the following ...NVIDIA Corporation Common Stock. $450.47 +0.42 +0.09%. MSFT. Microsoft Corporation Common Stock. $352.60 -0.20 -0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ... DocuSign (NASDAQ: DOCU) ... SDGR), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Amongst these choices, I would favor AbCellera Biologics in the current environment, ...Yet, risky stocks can also often offer attractive upside potential. Let's look at two examples: Recursion Pharmaceuticals ( RXRX 4.40%) and Madrigal Pharmaceuticals ( MDGL 1.83%). These two ...Jul 12, 2023 · Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year. Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty Pharma ...The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ...Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...Pre-Market Quotes Nasdaq-100 Ownership Search News + Insights Solutions Recursion Pharmaceuticals, Inc. Class A Common Stock P/E & PEG Ratios …When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related ...Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... Recursion Pharmaceuticals Inc (NASDAQ:RXRX). 7.38. Delayed Data. As of Dec 01. +0.53 / +7.74%. Today's Change. 4.54. Today|||52-Week Range. 16.75. -4.28%. Year- ...Microsoft Corporation Common Stock. $376.39 +0.22 +0.06%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.It plans to list on the Nasdaq under the symbol RXRX. Recursion Pharmaceuticals filed confidentially on January 26, 2021. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink and Allen ...12 Eyl 2023 ... The average price target on the stock suggests an 88% gain from recent prices. Expand. NASDAQ: RXRX. Recursion ...This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $9.00. The …Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements.Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock. Since then ...Jul 12, 2023 · RXRX.O. Official Data Partner. Latest Trade. trading higher 7.14 USD. Change 0.12 % Change + 1.71% Positive ... Nasdaq leads Wall St to higher close as CPI report lifts sentiment July 12, 2023. Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Nov 13, 2023 · The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ... Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Jul 12, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... A lot of healthcare companies are seeking to brandish their AI bonafides, but Recursion Pharmaceuticals (RXRX 7.88%), and GE Healthcare Technologies (GEHC 1.39%) are already using AI to boost ...(NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company …JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023.Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.If you're a biotech investor, you've probably heard of both Recursion Pharmaceuticals (NASDAQ: RXRX) and CRISPR Therapeutics, (NASDAQ: CRSP) two of the most followed biotechs this year. Both ...(NASDAQ:RXRX), which I spoke about on Aug. 8. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug ...Cathie Wood-led Ark Investment Management on Tuesday snapped up $27.2 million worth of shares in Tesla Inc (NASDAQ: ... (NASDAQ:RXRX) 908 Devices Inc (NASDAQ:MASS) 1life Healthcare Inc (NASDAQ:ONEM)On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the top stock picks of Samsara BioCapital along with IVERIC bio, Inc. (NASDAQ:ISEE), Sutro Biopharma, Inc. (NASDAQ:STRO) and Forma ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.RXRX Is Still Unprofitable. As a clinical stage biotech company, Recursion's financials are somewhat predictably steeped in red ink. The company has yet to report a profit - and even at that, its ...SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Track Recursion Pharmaceuticals Inc - Ordinary Shares - Class A (RXRX) Stock Price, Quote, latest community messages, chart, news and other stock related ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...... NASDAQ. Market Closed. RECURSION PHARMACEUTICALS INC (RXRX). 6.86 0.08 (1.18%) +0.08 (+1.18%) 0.08 (1.18%). As of 24 November 2023 02:00 PM EST. Currency USD.Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Average portfolio weight of all funds dedicated to RXRX is 0.77%, an increase of 46.27%. Total shares owned by institutions increased in the last three months by 18.96% to 141,638K shares.Mar 28, 2023 · Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Revenue Growth YOY: 291.46% Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company based in the United States. Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot ...Published: Nov 02, 2023. SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16, 2023.Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Nov 28, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Instantly RXRX has showed a red trend with a performance of -4.81% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 7.23 on Monday, 11/27/23 increased the stock’s daily price by 9.68%. SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Add to Watchlist. Add to Portfolio. RXRX RXRX AFTER HOURS QUOTE RXRX LATEST AFTER HOURS TRADES.Recursion Pharmaceuticals (NASDAQ:RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s stock .... Interactive brokers roth ira